| 265 | 0 | 17 |
| 下载次数 | 被引频次 | 阅读次数 |
慢性炎症、损伤和修复的反复恶性循环引起纤维化疾病的发生。越来越多的证据表明，组织损伤能够通过激活上皮-间充质转化（epithelial to mesenchymal transition,EMT）的方式促进纤维化进展，包括活化成纤维细胞、促进细胞迁移、侵袭以及加速细胞外基质的过度累积等。近来的研究发现钙库操纵性钙内流（store-operated calcium entry,SOCE）可促进EMT加剧纤维化疾病，通过抑制其信号转导具有防治纤维化的作用，其中，抗衰老蛋白Klotho可能存在调控SOCE进而防治纤维化疾病的作用。基于此，本文就近年来关于SOCE在纤维化疾病中对EMT的控制作用以及Klotho可能存在的调控作用进行简要综述，以期为进一步研究提供理论支持。
Abstract：The development of fibrotic diseases is often attributed to a recurrent cycle of chronic inflammation, injury, and repair. Growing evidence suggests that tissue injury can promote fibrosis progression by activating epithelial to mesenchymal transition(EMT), which involves fibroblast activation, cell migration and invasion, as well as excessive accumulation of extracellular matrix. Recent studies have shown that store-operated calcium entry(SOCE) promotes EMT and worsens fibrotic diseases, while inhibiting its signaling can help prevent and control fibrosis. In this context, the anti-aging protein Klotho may play a regulatory role in preventing and controlling fibrotic diseases by regulating SOCE. Therefore, this paper aims to review recent studies on the role of SOCE in regulating EMT in fibrotic diseases, as well as the potential regulatory function of Klotho, in order to offer theoretical support for future research.
1 Rubio K, Molina-Herrera A, Pérez-González A, et al.EP300 as a molecular integrator of fibrotic transcriptional programs[J]. Int J Mol Sci, 2023, 24(15):12302.
2 Xiong W, Xiong Z, Song A, et al. UCP1 alleviates renal interstitial fibrosis progression through oxidative stress pathway mediated by SIRT3 protein stability[J].J Translat Med, 2023, 21(1):521.
3 SzabóV, Csákány-Papp N, G?r?g M, et al. Orai1 calcium channel inhibition prevents progression of chronic pancreatitis[J]. JCI Insight, 2023, 8(13):e167645.
4 Hung Y, Chung CC, Chen YC, et al. Klotho modulates pro-fibrotic activities in human atrial fibroblasts through inhibition of phospholipase C signaling and suppression of store-operated calcium entry[J]. Biomedicines,2022, 10(7):1574.
5 Ling H, Xiao H, Luo T, et al. Role of ferroptosis in regulating the epithelial-mesenchymal transition in pulmonary fibrosis[J]. Biomedicines, 2023, 11(1):163.
6 Wang XC, Song K, Tu B, et al. New aspects of the epigenetic regulation of EMT related to pulmonary fibrosis[J]. Eur J Pharmacol, 2023, 956:175959.
7 Mottais A, Riberi L, Falco A, et al. Epithelial-mesenchymal transition mechanisms in chronic airway diseases:A common process to target[J]. Int J Mol Sci,2023, 24(15):12412.
8 Marconi GD, Fonticoli L, Rajan TS, et al. Epithelial-mesenchymal transition(EMT):The type-2 EMT in wound healing, tissue regeneration and organ fibrosis[J]. Cells, 2021, 10(7):1587.
9 Debnath P, Huirem RS, Dutta P, et al. Epithelial-mesenchymal transition and its transcription factors[J]. Biosci Rep, 2022, 42(1):BSR20211754.
10 Saitoh M. Epithelial-mesenchymal transition by synergy between transforming growth factor-β and growth factors in cancer progression[J]. Diagnostics(Basel, Switzerland), 2022, 12(9):2127.
11 Peng D, Fu M, Wang M, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]. Mol Cancer, 2022, 21(1):104.
12 Rhee KH, Yang SA, Pyo MC, et al. MiR-155-5p elevated by ochratoxin a induces intestinal fibrosis and epithelial-to-mesenchymal transition through TGF-β regulated signaling pathway in vitro and in vivo[J]. Toxins, 2023, 15(7):473.
13 Ali S, Rehman MU, Yatoo AM, et al. TGF-β signaling pathway:Therapeutic targeting and potential for anti-cancer immunity[J]. Eur J Pharmacol, 2023, 947:175678.
14 Roach KM, Bradding P. Ca2+signalling in fibroblasts and the therapeutic potential of K(Ca)3.1 channel blockers in fibrotic diseases[J]. British J Pharmacol, 2020,177(5):1003-1024.
15 Lemos FO, Bultynck G, Parys JB. A comprehensive overview of the complex world of the endo-and sarcoplasmic reticulum Ca2+-leak channels[J]. Biochim Biophy Acta Mol Cell Res, 2021, 1868(7):119020.
16 Masson B, Montani D, Humbert M, et al. Role of store-operated Ca2+entry in the pulmonary vascular remodeling occurring in pulmonary arterial hypertension[J]. Biomolecules, 2021, 11(12):1781.
17 Rubaiy HN. ORAI calcium channels:Regulation, function, pharmacology, and therapeutic targets[J]. Pharmaceuticals(Basel, Switzerland), 2023, 16(2):162.
18 Grabmayr H, Romanin C, Fahrner M. STIM proteins:An ever-expanding family[J]. Int J Mol Sci, 2020, 22(1):378.
19 Chanaday NL, Nosyreva E, Shin OH, et al. Presynaptic store-operated Ca2+entry drives excitatory spontaneous neurotransmission and augments endoplasmic reticulum stress[J]. Neuron, 2021, 109(8):1314-1332.e1315.
20 Li YY, Wang XJ, Su YL, et al. Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s[J]. Acta Pharmacol Sinica, 2022, 43(6):1495-1507.
21 Ong HL, Ambudkar IS. The endoplasmic reticulum-plasma membrane junction:A hub for agonist regulation of Ca2+entry[J]. Cold Spring Harbor Perspect Biol,2020, 12(2):a035253.
22 Wei J, Deng Y, Ye J, et al. Store-operated Ca2+entry as a key oncogenic Ca2+signaling driving tumor invasion-metastasis cascade and its translational potential[J]. Cancer Lett, 2021,516:64-72.
23 Heckman CA, Ademuyiwa OM, Cayer ML. How filopodia respond to calcium in the absence of a calcium-binding structural protein:Non-channel functions of TRP[J]. Cell Commun Signal, 2022, 20(1):130.
24 Lopez JJ, Jardin I, Sanchez-Collado J, et al. TRPC channels in the SOCE scenario[J]. Cells, 2020, 9(1):126.
25 Villalobo A, Ishida H, Vogel HJ, et al. Calmodulin as a protein linker and a regulator of adaptor/scaffold proteins[J]. Biochim Biophy Acta Mol Cell Res, 2018, 1865(3):507-521.
26 Bagur R, Hajnóczky G. Intracellular Ca2+sensing:Its role in calcium homeostasis and signaling[J]. Mol Cell,2017, 66(6):780-788.
27 Adiga D, Radhakrishnan R, Chakrabarty S, et al. The role of calcium signaling in regulation of epithelial-mesenchymal transition[J]. Cells Tissues Organs, 2022, 211(2):134-156.
28 Mo P, Yang S. The store-operated calcium channels in cancer metastasis:From cell migration, invasion to metastatic colonization[J]. Front Biosci(Landmark edition), 2018, 23(7):1241-1256.
29 Jin J, Ye M, Hu K, et al. STIM promotes the epithelial-mesenchymal transition of podocytes through regulation of FcγRII activity in diabetic nephropathy[J].Histol Histopathol, 2019, 34(6):671-682.
30 Hsu WL, Hsieh YC, Yu HS, et al. 2-Aminoethyl diphenylborinate inhibits bleomycin-induced skin and pulmonary fibrosis via interrupting intracellular Ca2+regulation[J]. J Dermatol Sci, 2021, 103(2):101-108.
31 Mai X, Shang J, Liang S, et al. Blockade of orai1store-operated calcium entry protects against renal fibrosis[J].JASN, 2016, 27(10):3063-3078.
32 Liu Y, Xie X, Wang P, et al. Mannan-binding lectin reduces epithelial-mesenchymal transition in pulmonary fibrosis via inactivating the store-operated calcium entry machinery[J]. J Innate Immun, 2023, 15(1):37-49.
33 Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho[J]. J Biol Chem, 2006, 281(10):6120-6123.
34 Puddu A, Maggi DC. Klotho:A new therapeutic target in diabetic retinopathy[J]. World J Diabetes, 2023, 14(7):1027-1036.
35 Abraham CR, Li A. Aging-suppressor klotho:Prospects in diagnostics and therapeutics[J]. Age Res Rev,2022, 82:101766.
36 Donate-Correa J, Martín-Carro B, Cannata-Andía JB,et al. Klotho, oxidative stress, and mitochondrial damage in kidney disease[J]. Antioxidants(Basel, Switzerland), 2023, 12(2):239.
37 Kim JH, Park EY, Hwang KH, et al. Soluble αKlotho downregulates orai1-mediated store-operated Ca2+entry via PI3K-dependent signaling[J]. Pflugers Arch, 2021,473(4):647-658.
38 Gui R, Li W, Li Z, et al. Effects and potential mechanisms of IGF1/IGF1R in the liver fibrosis:A review[J]. Int J Biol Macromol, 2023, 251:126263.
39 Zhang R, Li X, Gao Y, et al. Ginsenoside rg1 epigenetically modulates smad7 expression in liver fibrosis via MicroRNA-152[J]. J Ginseng Res, 2023, 47(4):534-542.
40 Kondo R, Kawata N, Suzuki Y, et al. Ca2+signaling and proliferation via Ca2+-sensing receptors in human hepatic stellate LX-2 cells[J]. Biol Pharmaceut Bullet,2022, 45(5):664-667.
41 Xia J, Zhu Z, Wen G, et al. Aberrant acetylated modification of FGF21-KLB signaling contributes to hepatocellular carcinoma metastasis through the β-catenin pathway[J]. Int J Oncol, 2023, 63(2):91.
42 Chi Z, Teng Y, Liu Y, et al. Association between klotho and non-alcoholic fatty liver disease and liver fibrosis based on the NHANES 2007-2016[J]. Annal Hepatol, 2023, 28(5):101125.
43 Guo H, Sun J, Zhang S, et al. Progress in understanding and treating idiopathic pulmonary fibrosis:Recent insights and emerging therapies[J]. Front Pharmacol,2023, 14:1205948.
44 Ortiz-Zapater E, Signes-Costa J, Montero P, et al.Lung fibrosis and fibrosis in the lungs:Is it all about myofibroblasts[J]. Biomedicines, 2022, 10(6):1423.
45 Yang W, Tian R, Zhu Y, et al. Paraquat is an agonist of STIM1 and increases intracellular calcium levels[J].Commun Biol, 2022, 5(1):1151.
46 Yu C, Zhou Z, Huang W, et al. Orai3 mediates Orai channel remodelling to activate fibroblast in pulmonary fibrosis[J]. J Cell Mol Med, 2022, 26(19):4974-4985.
47 Kulshrestha R, Singh H, Pandey A, et al. Caveolin-1 as a critical component in the pathogenesis of lung fibrosis of different etiology:Evidences and mechanisms[J].Exp Mol Pathol, 2019, 111:104315.
48 Huang Q, Chen Y, Shen S, et al. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production:A therapeutic implication for idiopathic pulmonary fibrosis[J]. Aging, 2020, 12(7):5812-5831.
49 Tavares de Sousa H, Magro F. How to evaluate fibrosis in IBD[J]. Diagnostics(Basel, Switzerland), 2023, 13(13):2188.
50 Letizia M, Wang YH, Kaufmann U, et al. Store-operated calcium entry controls innate and adaptive immune cell function in inflammatory bowel disease[J]. EMBO Mol Med, 2022, 14(9):e15687.
51 Thurston RD, Larmonier CB, Majewski PM, et al. Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis[J]. Gastroenterology, 2010,138(4):1384-1394.
52 Sariboyaci AE, Uysal O, Soykan MN, et al. The potential therapeutic effect of klotho on cell viability in human colorectal adenocarcinoma HT-29 cells[J]. Med Oncol(Northwood, London, England), 2022, 39(12):191.
53 Gunes S, Soykan MN, Sariboyaci AE, et al. Enhancement of Apo2L/TRAIL signaling pathway receptors by the activation of klotho gene with CRISPR/Cas9 in Caco-2 colon cancer cells[J]. Med Oncol(Northwood,London, England), 2021, 38(12):146.
54 Liu Y, Lei H, Zhang W, et al. Pyroptosis in renal inflammation and fibrosis:Current knowledge and clinical significance[J]. Cell Death Dis, 2023, 14(7):472.
55 Tao Y, Yazdizadeh Shotorbani P, Inman D, et al.Store-operated Ca2+entry inhibition ameliorates high glucose and ANGⅡ-induced podocyte apoptosis and mitochondrial damage[J]. Am J Physiol Renal Physiol,2023, 324(5):F494–F504.
56 Fu Y, Cao J, Wei X, et al. Klotho alleviates contrast-induced acute kidney injury by suppressing oxidative stress, inflammation, and NF-KappaB/NLRP3-mediated pyroptosis[J]. Int Immunopharmacol, 2023, 118:110105.
57 Takenaka T, Hasan A, Marumo T, et al. Klotho supplementation reverses renal dysfunction and interstitial fibrosis in remnant kidney[J]. Kidney Blood Pressure Res, 2023, 48(1):326-337.
58 Li Y, Xue M, Hu F, et al. Klotho prevents epithelial-mesenchymal transition through Egr-1 downregulation in diabetic kidney disease[J]. BMJ Open Diabetes Res Care, 2021, 9(1):e002038.
59 Lin LC, Tu B, Song K, et al. Mitochondrial quality control in cardiac fibrosis:Epigenetic mechanisms and therapeutic strategies[J]. Metabolism, 2023, 145:155626.
60 Li JM, Chen FF, Li GH, et al. Soluble Klotho-integrinβ1/ERK1/2 pathway ameliorates myocardial fibrosis in diabetic cardiomyopathy[J]. FASEB J, 2021, 35(11):e21960.
61 Wang K, Li Z, Li Y, et al. Cardioprotection of Klotho against myocardial infarction-induced heart failure through inducing autophagy[J]. Mechanisms Ageing Dev, 2022, 207:111714.
62 Richter B, Faul C. FGF23 actions on target tissues-with and without klotho[J]. Front Endocrinol, 2018, 9:189.
63 Glosse P, Feger M, Mutig K, et al. AMP-activated kinase is a regulator of fibroblast growth factor 23 production[J]. Kidney Int, 2018, 94(3):491-501.
64 Ewendt F, Hirche F, Feger M, et al. Peroxisome proliferator-activated receptor α(PPARα)-dependent regulation of fibroblast growth factor 23(FGF23)[J].Pflugers Archiv, 2020, 472(4):503-511.
65 Yuan Q, Ren Q, Li L, et al. A klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling[J]. Nature Commun, 2022, 13(1):438.
基本信息:
DOI：10.13210/j.cnki.jhmu.20240830.003
中图分类号:R363
引用信息:
[1]刘禹杉,杨树森,张仪霖,等.Klotho靶向钙库操纵性钙内流调控上皮-间充质转化治疗纤维化疾病的研究进展[J].海南医科大学学报,2025,31(01):73-80.DOI:10.13210/j.cnki.jhmu.20240830.003.
基金信息:
国家自然科学基金资助项目（81873233、82174330）; 陕西中医药大学科技创新团队（2023-CXTD-01）~~
2024-09-01
2024-09-01
2024-09-01